Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor - PubMed (original) (raw)

Comparative Study

. 2008 Jun;47(6):1924-35.

doi: 10.1002/hep.22252.

I-Chen Yu, Ruey-Shen Wang, Yei-Tsung Chen, Ning-Chun Liu, Saleh Altuwaijri, Cheng-Lung Hsu, Wen-Lung Ma, Jenny Jokinen, Janet D Sparks, Shuyuan Yeh, Chawnshang Chang

Affiliations

Comparative Study

Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor

Hung-Yun Lin et al. Hepatology. 2008 Jun.

Abstract

Early studies demonstrated that whole-body androgen receptor (AR)-knockout mice with hypogonadism exhibit insulin resistance. However, details about the mechanisms underlying how androgen/AR signaling regulates insulin sensitivity in individual organs remain unclear. We therefore generated hepatic AR-knockout (H-AR(-/y)) mice and found that male H-AR(-/y) mice, but not female H-AR(-/-) mice, fed a high-fat diet developed hepatic steatosis and insulin resistance, and aging male H-AR(-/y) mice fed chow exhibited moderate hepatic steatosis. We hypothesized that increased hepatic steatosis in obese male H-AR(-/y) mice resulted from decreased fatty acid beta-oxidation, increased de novo lipid synthesis arising from decreased PPARalpha, increased sterol regulatory element binding protein 1c, and associated changes in target gene expression. Reduced insulin sensitivity in fat-fed H-AR(-/y) mice was associated with decreased phosphoinositide-3 kinase activity and increased phosphenolpyruvate carboxykinase expression and correlated with increased protein-tyrosine phosphatase 1B expression.

Conclusion: Together, our results suggest that hepatic AR may play a vital role in preventing the development of insulin resistance and hepatic steatosis. AR agonists that specifically target hepatic AR might be developed to provide a better strategy for treatment of metabolic syndrome in men.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources